

# NEWS RELEASE

MAY 7, 2013



## **Response Biomedical Corp. Schedules First Quarter 2013 Earnings Release and Conference Call and Announces Participation in Upcoming Investor Conference**

**Vancouver, British Columbia, May 7, 2013** – Response Biomedical Corp. (“Response”) (TSX: RBM, OTCBB: RPBIF) will release its first quarter 2013 financial results after the markets close on Monday, May 13, 2013.

Jeffrey L. Purvin, Chief Executive Officer, will host a conference call to discuss the Q1, 2013 financial results on May 13, 2013 at 2:00 p.m. PDT (5:00 p.m. EDT), shortly after the initial release. Also participating in the call will be Bill Adams, Chief Financial Officer.

The conference call will be webcast live and is also available by dialing 1-877-643-7155 in North America or 1-914-495-8552 for all other locations. The conference ID number is 64770721 and participants are encouraged to initiate their calls at least 10 minutes in advance of the 2:00 p.m. PDT (5:00 p.m. EDT) start time to ensure a timely connection.

The live webcast and earnings release will be accessible from our website: [www.responsebio.com/events](http://www.responsebio.com/events). A replay of the conference call will also be available online approximately two hours after the call and for 90 days thereafter.

Additionally, Response announces that Jeffrey L. Purvin, Chief Executive Officer, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference to be held at the Toronto Board of Trade, Toronto, Ontario, Canada, on Wednesday, May 22, 2013 at 3:30 p.m. EDT.

### **About Response Biomedical Corp.**

Response develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical, biodefense and environmental applications. RAMP® represents a unique paradigm in diagnostics that provides reliable laboratory quality results in minutes. The RAMP® Platform consists of a reader and single-use disposable test cartridges and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, Flu A + B and RSV. In the non-clinical market, RAMP® tests are currently available for the environmental detection of West Nile Virus and for Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.

Response is a publicly traded company listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at [www.responsebio.com](http://www.responsebio.com).

# NEWS RELEASE

MAY 7, 2013



## Forward-Looking Statements

Certain statements contained in this news release constitute forward-looking information or forward-looking statements (collectively, “forward-looking statements”) with the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “believe”, “may”, “will”, “project”, “anticipate”, “continue”, “estimate”, “expect”, “intend” and other similar words suggesting future events or future performance. Forward-looking statements are based on assumptions made by the Company regarding various matters. Although the Company believes the expectations reflected in such forward-looking statements, and the assumptions upon which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct.

Readers are cautioned not to place undue reliance on forward-looking statements included in this news release, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many factors may cause the Company’s actual results to differ materially from any forward-looking statement, including the factors detailed in the Company’s filings with the Securities and Exchange Commission and Canadian Securities regulatory authorities, including but not limited to our annual report on Form 10-K, our quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission and Canadian securities regulatory authorities.

The forward-looking statements contained in this news release are current as of the date hereof and are qualified in their entirety by this cautionary statement. Except as expressly required by applicable securities laws, the Company does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

**Response Biomedical Corp.**

Patricia Massitti, 604-456-6010

VP, HR & Corporate Communications

[ir@responsebio.com](mailto:ir@responsebio.com)